EP1363993A4 - Verfahren zur behandlung von entzündungs- und immunkrankheiten unter verwendung der i kappa b-kinase (ikk) - Google Patents

Verfahren zur behandlung von entzündungs- und immunkrankheiten unter verwendung der i kappa b-kinase (ikk)

Info

Publication number
EP1363993A4
EP1363993A4 EP02714815A EP02714815A EP1363993A4 EP 1363993 A4 EP1363993 A4 EP 1363993A4 EP 02714815 A EP02714815 A EP 02714815A EP 02714815 A EP02714815 A EP 02714815A EP 1363993 A4 EP1363993 A4 EP 1363993A4
Authority
EP
European Patent Office
Prior art keywords
ikk
kinase
inhibitors
methods
treating inflammatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02714815A
Other languages
English (en)
French (fr)
Other versions
EP1363993A2 (de
Inventor
James R Burke
Steven Nadler
Yuping Qiu
Robert M Townsend
Fred Christopher Zusi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/965,977 external-priority patent/US6960585B2/en
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of EP1363993A2 publication Critical patent/EP1363993A2/de
Publication of EP1363993A4 publication Critical patent/EP1363993A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EP02714815A 2001-02-01 2002-02-01 Verfahren zur behandlung von entzündungs- und immunkrankheiten unter verwendung der i kappa b-kinase (ikk) Withdrawn EP1363993A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US26585301P 2001-02-01 2001-02-01
US265853P 2001-02-01
US965977 2001-09-27
US09/965,977 US6960585B2 (en) 2000-10-03 2001-09-27 Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same
PCT/US2002/003060 WO2002060386A2 (en) 2001-02-01 2002-02-01 METHODS OF TREATING INFLAMMATORY AND IMMUNE DISEASES USING INHIBITORS OF IλB KINASE (IKK)

Publications (2)

Publication Number Publication Date
EP1363993A2 EP1363993A2 (de) 2003-11-26
EP1363993A4 true EP1363993A4 (de) 2008-11-12

Family

ID=26951465

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02714815A Withdrawn EP1363993A4 (de) 2001-02-01 2002-02-01 Verfahren zur behandlung von entzündungs- und immunkrankheiten unter verwendung der i kappa b-kinase (ikk)

Country Status (10)

Country Link
EP (1) EP1363993A4 (de)
JP (1) JP2004529088A (de)
AU (1) AU2002247059B2 (de)
CA (1) CA2436770A1 (de)
CZ (1) CZ20032287A3 (de)
HU (1) HUP0304045A3 (de)
MX (1) MXPA03006817A (de)
NO (1) NO20033429L (de)
PL (1) PL364111A1 (de)
WO (1) WO2002060386A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002028860A2 (en) * 2000-10-03 2002-04-11 Bristol-Myers Squibb Company Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same
IL155519A0 (en) 2000-10-26 2003-11-23 Tularik Inc Antiinflammation agents
US7176314B2 (en) 2001-12-05 2007-02-13 Amgen, Inc. Inflammation modulators
DE10237722A1 (de) 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
US7199119B2 (en) 2002-10-31 2007-04-03 Amgen Inc. Antiinflammation agents
PE20060373A1 (es) 2004-06-24 2006-04-29 Smithkline Beecham Corp Derivados 3-piperidinil-7-carboxamida-indazol como inhibidores de la actividad cinasa de ikk2
TW200626142A (en) 2004-09-21 2006-08-01 Glaxo Group Ltd Chemical compounds
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
CN101247804B (zh) 2005-06-30 2012-09-26 史密丝克莱恩比彻姆公司 化学化合物
EP2266561A3 (de) * 2005-09-07 2011-05-18 Merck Serono S.A. IKK-Inhibitoren zur Behandlung von Endometriose
US20090175852A1 (en) 2006-06-06 2009-07-09 Schering Corporation Imidazopyrazines as protein kinase inhibitors
CN101553491B (zh) * 2006-12-13 2013-05-29 Aska制药株式会社 喹喔啉衍生物
AR065804A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
EP2278999A4 (de) 2008-04-21 2015-04-22 Otonomy Inc Ohrbehandlungsformulierungen zur behandlung von ohrenerkrankungen und -leiden
WO2010000903A2 (es) * 2008-06-30 2010-01-07 Centro De Investigaciones Energéticas, Medioambientales Y Tecnológicas (Ciemat) Composición capaz de modular la actividad de ikkalpha para el tratamiento de enfermedades que cursan con acantolisis
RU2504544C2 (ru) 2008-10-02 2014-01-20 Асахи Касеи Фарма Корпорейшн 8-замещенные производные изохинолина и их применение
JP2012520257A (ja) 2009-03-10 2012-09-06 グラクソ グループ リミテッド Ｉｋｋ２阻害剤としてのインドール誘導体
WO2018005830A1 (en) 2016-06-29 2018-01-04 Otonomy, Inc. Triglyceride otic formulations and uses thereof
EP3494994A1 (de) * 2017-12-07 2019-06-12 Universität zu Köln Kombinationen von ripk1 und ikk-hemmern zur vorbeugung und behandlung von immunerkrankungen

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002028860A2 (en) * 2000-10-03 2002-04-11 Bristol-Myers Squibb Company Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4160097A (en) * 1977-01-07 1979-07-03 Westwind Pharmaceuticals, Inc. 1-(2-Phenylureylene)imidazoles
US5851812A (en) * 1997-07-01 1998-12-22 Tularik Inc. IKK-β proteins, nucleic acids and methods
US6235740B1 (en) * 1997-08-25 2001-05-22 Bristol-Myers Squibb Co. Imidazoquinoxaline protein tyrosine kinase inhibitors
US6030834A (en) * 1997-12-30 2000-02-29 Chiron Corporation Human IKK-beta DNA constructs and cells
GB0003154D0 (en) * 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
AU3741801A (en) * 2000-03-15 2001-09-24 Aventis Pharma Gmbh Substituted beta-carbolines with ikb-kinase inhibiting activity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002028860A2 (en) * 2000-10-03 2002-04-11 Bristol-Myers Squibb Company Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TSAI S -H ET AL: "Suppression of TNF[alpha]-mediated NF[kappa]B activity by myricetin and other flavonoids through downregulating the activity of IKK in ECV304 cells", JOURNAL OF CELLULAR BIOCHEMISTRY 19990915 US, vol. 74, no. 4, 15 September 1999 (1999-09-15), pages 606 - 615, XP002497486, ISSN: 0730-2312 *

Also Published As

Publication number Publication date
PL364111A1 (en) 2004-12-13
CA2436770A1 (en) 2002-08-08
WO2002060386A2 (en) 2002-08-08
NO20033429D0 (no) 2003-07-31
NO20033429L (no) 2003-09-24
MXPA03006817A (es) 2003-11-13
EP1363993A2 (de) 2003-11-26
AU2002247059B2 (en) 2006-11-16
WO2002060386A3 (en) 2002-10-10
HUP0304045A2 (hu) 2004-04-28
JP2004529088A (ja) 2004-09-24
CZ20032287A3 (cs) 2004-02-18
HUP0304045A3 (en) 2005-05-30

Similar Documents

Publication Publication Date Title
EP1363993A4 (de) Verfahren zur behandlung von entzündungs- und immunkrankheiten unter verwendung der i kappa b-kinase (ikk)
GB2393202B (en) Methods of well treatment
EP1572116A4 (de) Zusammensetzungen und verfahren für die behandlung von immunkrankheiten
EP1444204A4 (de) Proteinkinase- und -phosphataseinhibitoren, verfahren zu deren entwicklung und verfahren zu deren verwendung
PL367272A1 (en) Novel substituted benzimidazole dosage forms and method of using same
EP1383743A4 (de) Duale inhibitoren von pde 7 und pde 4
IL161775A0 (en) Topical compositions and methods for treatment of adverse effects ofionizing radiation
AU2002364364A8 (en) Method of treating apoptosis and compositions thereof
IL148034A0 (en) Methods of treating nuclear factor-kappa b mediated diseases and disorders
HK1080382A1 (en) Compositions and methods for treatment of hyperplasia
EP1363702A4 (de) Verfahren zur hemmung von kinasen
AU2003206785A1 (en) Use of tyrosine kinase inhibitors for the treatment of inflammatory processes
NO20043085L (no) Fremgangsmater og sammensetninger for behandling av forstyrrelser i sentralnervesystemet
NO20033854D0 (no) N-but-3-enyl-norbuprenorfin og fremgangsmåter for anvendelse
EP1520043A4 (de) VERFAHREN ZUR IDENTIFIKATION DER IKKa-FUNKTION UND ANDERER GENE ZUR BEHANDLUNG VON ENTZÜNDLICHEN ERKRANKUNGEN
HUP0401392A3 (en) Use of composition comprising anti-hla-antibody for treatment of diseases involving prolierative immune response
EP1578373A4 (de) Neue zusammensetzungen und verfahren zur behandlung von erkrankungen des immunsystems
IL155174A0 (en) Methods and compositions for the treatment of inflammatory diseases
AU2003210983A8 (en) Kinase inhibitors and methods of use thereof
EP1416795A4 (de) Zusammensetzungen und verfahren zur behandlung von krankheiten der mitochondrien
EP1424897A4 (de) Zusammensetzungen und verfahren zur behandlung von krebs
EP1515707A4 (de) Verfahren zur behandlung von atherosklerose und anderer entzündlicher erkrankungen
PL368035A1 (en) Compositions and methods for the treatment of cancer
EP1472273A4 (de) Zusammensetzungen und verfahren zur behandlung von immunerkrankungen
EP1562587A4 (de) Neue zusammensetzungen und verfahren zur behandlung von immunkrankheiten

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030829

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 37/00 20060101ALI20080930BHEP

Ipc: A61P 29/00 20060101ALI20080930BHEP

Ipc: A61K 31/519 20060101ALI20080930BHEP

Ipc: A61K 31/4985 20060101ALI20080930BHEP

Ipc: A61K 31/4745 20060101ALI20080930BHEP

Ipc: C07D 487/04 20060101ALI20080930BHEP

Ipc: C12N 15/54 20060101ALI20080930BHEP

Ipc: C12N 9/12 20060101ALI20080930BHEP

Ipc: C12N 5/10 20060101ALI20080930BHEP

Ipc: C12N 1/21 20060101AFI20030912BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20081010

17Q First examination report despatched

Effective date: 20090205

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100209